Chapter 15 Structure-Based Design of New Antibacterial Agents

Annual Reports in Computational Chemistry

Volumn 2, Issue C, 2006, Pages 279-295

  Ni, Haihong ^a   Wendoloski, John ^a  

^a ASTRAZENECA   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 77956747447     PISSN: 15741400     EISSN: None     Source Type: Book Series    
DOI: 10.1016/S1574-1400(06)02015-9     Document Type: Review

References (63)

1. Diekema D.I. Oxazolinonones: a review. Drugs 59 (2000) 7-16
2. Applebaum P.C., and Hunter P.A. The fluoroquinolone antibacterials: past, present and future perspective. Int. J. Antimicrob. Agents 16 (2000) 5-15
3. Cassell G.H., and Mekalanos J. Development of antimicrobial agents in the era of new and reemerging infectious diseases and increasing antibiotic resistance. J. Am. Med. Assoc. 285 (2001) 601-605
4. Mills S. The role of genomics in antimicrobial discovery. J. Antimicrob. Chemother. 51 (2003) 749-752
5. Bailey D., and Brown D. High-throughput chemistry and structure-based design: survival of the smartest. Drug Discov. Today. 6 (2001) 57-59
6. Schneider G., and Böhm H.J. Virtual screening and fast automated docking methods. Drug Discov. Today 7 (2002) 64-70
7. Champoux J.J. DNA topoisomerases: structure, function, and mechanism. Ann. Rev. Biochem. 70 (2001) 369-413
8. Maxwell A. DNA gyrase as a drug target. Trends Microbiol. 5 (1997) 102-109
9. F. O'Grady, Coumarins. In: Antibiotic and Chemotherapy (ed.), F. O'Grady, H. P. Lambert, R. G. Finch and L. S. Greenwood), Churchill Livingstone, Edinburgh, 1997, 7th edition, pp. 333-335.
10. Steiger M., Angehren P., Wohlgensinger B., and Gmunder H. GyrB mutations in Staphylococcus aureus strains resistant to cyclothialidine, coumermycin, and novobiocin. Antimicrob. Agents Chemother. 40 (1996) 1060-1062
11. Block M., and Nichols W. Design of antibacterial agents. Mol. Med. Microbiol. 1 (2002) 609-626
12. A. L. Breeze, O. M. Green, K. G. Hull, H. Ni, S. I. Hauck, G. B. Mullen, N. J. Hales and D. Timms, Preparation of pyrroles as antibacterial agents, PCT Int. Appl., 2005, WO 2005026149.
13. K. Yager, S. Chu, K. Appelt and X. Li, Preparation of thiazolylindazoles as inhibitors of bacterial DNA gyrase B inhibitors, U.S. Pat. Appl. Publ., 2005, US2005 054697.
14. P. Charifson, D. D. Deininger, J. Drumm, A. Grillot and Y. Liao, P. Oliver-Shaffer, D. Stamos, Preparation of 2-ureido-6-heteroaryl-3H-benzimidazole-4-carboxylic acid derivatives and related compounds as gyrase and/or topoisomerase IV inhibitors for the treatment of bacterial infections, U.S. Pat. Appl. Publ., 2004, US2004 0235886.
15. A. Grillot, D. Stamos, T. Grossman, Y. Bi, M. Carver, D. Deininger, J. Drumm, C. Gross, A. Letiran, Y. Liao, N. Mani, J. Moore, D. Nicolau, E. Olson, J. Parsons, J. Partaledis, E. Perola, S. Ronkin, Q. Tang, S. Tian, P. Tessier, T. Wang, Y. Wei, H. Zhang, and P. Charifson, A new class of dual targeting inhibitors of GyrB and ParE. F-1951, 44th ICAAC, 2004.
16. Boehm H., Boehringer M., Bur D., Gmuender H., Huber W., Klaus W., Kostrewa D., Kuehne H., Luebbers T., Meunier-Keller N., and Mueller F. Novel inhibitors of DNA gyrase: 3D structure based biased needle screening, hit validation by biophysical methods, and 3D guided optimization. A promising alternative to random screening. J. Med. Chem. 43 (2000) 2664-2674
17. Tanitame A., Oyamada Y., Ofuju K., Kyoya Y., Suzuki K., Ito H., Kawasaki M., Nagai K., Wachi M., and Yamagishi J. Design, synthesis and structure-activity relationship studies of novel indazole analogues as DNA gyrase inhibitors with Gram-positive antibacterial activity. Bioorg. Med. Chem. Lett. 14 (2004) 2857-2862
18. Musicki B., Periers A.M., Laurin P., Ferroud D., Benedetti Y., Lachaud S., Chatreaux F., Haesslein J.L., Iltis A., Pierre C., Khider J., Tessot N., Airault M., Demassey J., Dupuis-Hamelin C., Lassaigne P., Bonnefoy A., Vicat P., and Klich M. Improved antibacterial activities of courmarin antibiotics bearing 5′, 5′-dialkylnoviose: biological activity of RU79115. Bioorg. Med. Chem. Lett. 10 (2000) 1695-1699
19. Annedi S.C., and Kotra L.P. RU-79115 Aventis Pharma. Curr. Opin. Investig. Drugs 2 (2001) 752-754
20. Angehrn P., Buchmann S., Funk C., Goetschi E., Gmuender H., Hebeisen P., Kostrewa D., Link H., Luebbers T., Masciadri R., Nielsen J., Reindl P., Ricklin F., Schmitt-Hoffmann A., and Theil F.P. New antibacterial agents derived from the DNA gyrase inhibitor cyclothialidine. J. Med. Chem. 47 (2004) 1487-1513
21. Lewis R.J., Singh O.M.P., Smith C.V., Skarzynski T., Maxwell A., Wonacott A.J., and Wigley D.B. The nature of inhibition of DNA gyrase by the coumarins and the cyclothialidines revealed by X-ray crystallography. EMBO J. 15 (1996) 1412-1420
22. Tsai F.T., Singh O.M.P., Skarzynski T., Wonacott A.J., Weston S., Tucker A., Pauptit R.A., Breeze A.L., Poyser J.P., O'Brien R., Ladbury J.E., and Wigley D.B. The high-resolution crystal structure of a 24-kDa gyrase B fragment from E. coli complexed with one of the most potent coumarin inhibitors, clorobiocin. Proteins 28 (1997) 41-52
23. Wigley D.B., Davis G., Donson E.J., Maxwell A., and Dodson G. Crystal structure of an N-terminal fragment of the DNA gyrase B protein. Nature 351 (1991) 624-629
24. Schechner M., Sirockin F., Stote R.H., and Dejaegere A.P. Functionality maps of the ATP binding site of DNA Gyrase B: generation of a consensus model of ligand binding. J. Med. Chem. 47 (2004) 4373-4390
25. Miranker A., and Karplus M. Functionality maps of binding sites: a multiple copy simultaneous search method. Prot.: Struc., Func. Genet. 11 (1991) 29-34
26. Jones G., Willett P., Glen R.C., Leach A.R., and Taylor R. Development and validation of a genetic algorithm for flexible docking. J. Mol. Biol. 267 (1997) 727-748
27. Morris G.M., Goodsell D.S., Huey R., and Olsen A.J. Distributed automated docking of flexible ligands to proteins: parallel application of AutoDock 2.4. J. Comput.-Aided Mol. Des. 10 (1996) 293-304
28. FRED OpenEye, Santa Fe NM, 2003. http://www.eyesopen.com/
29. Rarey M., Kramer B., Lengauer T., and Klebe G. A fast flexible docking method using an incremental construction algorithm. J. Mol. Biol. 261 (1996) 470-489
30. G. L. Warren, C. W. Andrews, A. Capelli, B. Clarke, J. LaLonde, M. H. Lambert, M. Lindvall, N. Nevins, S. F. Semus, S. Senger, G. Tedesco, I. D. Wall, J. M. Woolven, C. E. Peishoff and M. S. Head, A critical assessment of docking programs and scoring functions, J. Med. Chem., 2005, ASAP Article. http://pubs3.acs.org/acs/journals/doilookup?in_doi=10.1021/jm050362n.
31. Schulz-Gasch T., and Stahl M. Binding site characteristics in structure-based virtual screening: evaluation of current docking tools. J. Mol. Model. 9 (2003) 47-57
32. McMartin C., and Bohacek R.J. QXP: powerful, rapid computer algorithms for structure-based drug design. J. Comput.-Aided Mol. Des. 11 (1997) 333-344
33. Friesner R.A., Banks J.L., Murphy R.B., Halgren T.A., Klicic J.J., Mainz D.T., Repasky M.P., Knoll E.H., Shelley M., Perry J.K., Shaw D.E., Francis P., and Shenkin P.S. Glide: a new approach for rapid, accurate docking and scoring. 1. Method and assessment of docking accuracy. J. Med. Chem. 47 (2004) 1739-1749
34. -J Böhm H. The computer program LUDI: a new method for the de novo design of enzyme inhibitors. J. Comput.-Aided Mol. Des. 6 (1992) 61-78
35. Sprague P. Automated chemical hypothesis generation and database searching with CATALYST. Perspect, Drug Discov. Des. 3 (1995) 1-20
36. Pierce A.C., Rao G., and Bemis G.W. BREED: generating novel inhibitors through hybridization of known ligands. J. Med. Chem. 47 (2004) 2768-2775
37. Meinnel T., Mechulam Y., and Blanquet S. Methionine as translational start signal: a review of the enzymes the pathway in. E. coli, Biochimie. 75 (1993) 1061-1075
38. Yuan Z., Trias J., and White R.J. Deformylase as a novel antibacterial target. Drug Discov. Today 6 (2001) 954-961
39. Waller A.S., and Clements J.M. Novel approaches to antimicrobial therapy: peptide deformylase. Curr. Opin. Drug Discov. Dev. 5 (2002) 785-792
40. Rajagopalan P.T.R., Yu X.C., and Pei D. Peptide deformylase: a new type of mononuclear iron protein. J. Am. Chem. Soc. 119 (1997) 12418-12419
41. Clements J.M., Beckett R.P., Brown A., Catlin G., Lobell M., Palan S., Thomas W., Whittaker M., Wood S., Salama S., Baker P.J., Rodgers H.F., Barynin V., Rice D.W., and Hunter M.G. Antibiotic activity and characteristic of BB-3497, a novel peptide deformylase inhibitor. Antimicrob. Agents Chemother. 45 (2001) 563-570
42. Hao B., Gong W., Rajagopalan P.T.R., Zhou Y., Pei D., and Chan M.K. Structural basis for the design of antibiotics targeting peptide deformylase. Biochemistry 38 (1999) 4712-4719
43. -P. Guilloteau J., Mathieu M., Giglione C., Blanc V., Dupuy A., Chevrier M., Gil P., Famechon A., Meinnel T., and Mikol V. The crystal structures of four peptide deformylases bound to the antibiotic actinonin reveal two distinct types: a platform for the structural-based design of antibacterial agents. J. Mol. Biol. 320 (2002) 951-962
44. Beckett R.P., Davidson A.H., Drummond A.H., Huxley P., and Whittake M. Recent advances in matrix metalloproteinase inhibitor research. Drug Discov. Today 1 (1996) 16-26
45. Meinnel T., Patiny L., Ragusa S., and Blanquet S. Design and synthesis of substrate analogue inhibitors of peptide deformylase. Biochemistry 38 (1999) 4287-4295
46. Wei Y., Yi T., Huntington K.M., Chaudhury C., and Pei D. Identification of a potent peptide deformylase inhibitor from a rationally designed combinatorial library. J. Comb. Chem. 2 (2000) 650-657
47. Chen D.Z., Patel D.V., Hackbarth C.J., Wang W., Dreyer G., Young D., Margolis P.S., Wu C., Ni Z.J., Trias J., White R., and Yuan Z. Actinonin, a naturally occurring antibacterial agent, is a potent deformylase inhibitor. Biochemistry 39 (2000) 1256-1262
48. Chen D.Z., Hackbarth C., Ni Z.J., Wu C., Wang W., Jain R., He Y., Bracken K., Weidmann B., Patel D.V., Trias J., White R.J., and Yuan Z. Peptide deformylase inhibitors as antibacterial agents: identification of VRC-3375, a proline-3-alkylsuccinyl hydroxomate derivative, by using an integrated combinatorial and medicinal chemistry approach. Antimicrob. Agents Chemother. 48 (2004) 250-261
49. Apel C.M., Banner D.W., Bur D., Dietz M., Hirata T., Hubschwerlen C., Locher H., Page M.G.P., Pirson W., Rosse G., and Specklin J.L. Hydroxamic acid derivatives as potent peptide deformylase inhibitors and antibacterial agents. J. Med. Chem. 43 (2000) 2324-2331
50. Mclntyre J.A., Castaner J., and Martin L. LBM-415 antibacterial peptide deformylase inhibitor. Drug Future 30 (2005) 23-28
51. Fritsche T.R., Sader H.S., Cleeland R., and Jones R.N. Comparative antimicrobial characterization of LBM-415 (NVP PDF-713), a new peptide deformylase inhibitor of clinical importance. Antimicrob. Agents Chemother. 49 (2005) 1468-1476
52. Davies S.J., Ayscough A.P., Beckett R.P., Clements J.M., Doel S., Pratt L.M., Spavold A.M., Thomas S.W., and Whittaker M. Structure-activity relationships of the peptide deformylase inhibitor BB-3497: modification of the methylene spacer and the P1′ side chain. Bioorg. Med. Chem. Lett. 13 (2003) 2715-2718
53. Jain R., Chen D., White R.J., Patel D.V., and Yuan Z. Bacterial peptide deformylase inhibitors: a new class of antibacterial agents. Curr. Med. Chem. 12 (2005) 1607-1621
54. Murphy R.B., Philipp D.M., and Friesner R.A. Mixed quantum mechanics/molecular mechanics (QM/MM) method for large-scale modeling of chemistry in protein environment. J. Comp. Chem. 21 (2001) 1442-1457
55. Madison V., Duca J., Bennett F., Bohanon S., Cooper A., Chu M., Desai J., Girijavallabhan V., Hare R., Hruza A., Hendrata S., Huang Y., Kravec C., Malcolm B., McCormick J., Miesel L., Ramanathan L., Reichert P., Saksena A., Wang J., Weber P.C., Zhu H., and Fischmann T. Binding affinities and geometries of various metal ligands in peptide deformylase inhibitors. Biophys. Chem. 101-102 (2002) 239-247
56. Hu X., Nguyen K.T., Jiang V.C., Lofland D., Moser H., and Pei D. Macrocyclic inhibitors for pepetide deformylase: a structure-activity relationship study of the ring size. J. Med. Chem. 47 (2004) 4941-4949
57. Hu X., Nguyen K.T., Verlinde C.L.M.J., Hol W.G., and Pei D. Structure-based design of a macrocyclic inhibitor for peptide deformylase. J. Med. Chem. 46 (2003) 3771-3774
58. Molteni V., He X., Nabakka J., Yang K., Kreusch A., Gordon P., Bursulaya B., Warner I., Shin T., Biorac T., Ryde N.S., Goldberg R., Doughty J., and He Y. Identification of novel potent bicyclic peptide deformylase inhibitors. Bioorg. Med. Chem. Lett. 14 (2004) 1477-1481
59. Gupta M.K., Mishra P., Prathipati P., and Saxena A.K. 2D-QSAR in hydroxamic acid derivatives as peptide deformylase inhibitors and antibacterial agents. Bioorg. Med. Chem. Lett. 10 (2002) 3713-3716
60. Smith H.K., Beckett R.P., Clements J.M., Doel S., East S.P., Launchbury S.B., Pratt L.M., Spavold Z.M., Thomas W., Todd R.S., and Whittaker M. Structure-activity relationships of the peptide deformylase inhibitor BB-3497: modification of the metal binding group. Bioorg. Med. Chem. Lett. 12 (2002) 3595-3599
61. Davies S.J., Ayscough A.P., Beckett R.P., Bragg R.A., Clements J.M., Doel S., Grew C., Launchbury S.B., Perkins G.M., Pratt L.M., Smith H.K., Spavold Z.M., Thomas S.W., Todd R.S., and Whittaker M. Structure-activity relationships of the peptide deformylase inhibitor BB-3497: modification of the methylene spacer and the P1′ side chain. Bioorg. Med. Chem. Lett. 13 (2003) 2709-2713
62. Chang G., and Roth C.B. Structure of MsbA from E. coli: a homolog of the multidrug resistance ATP binding cassette. Science 293 (2001) 1793-1800
63. Akama H., Matsuura T., Kashiwagi S., Yoneyama H., Narita S., Tsukihara T., Nakagawa A., and Nakae T. Crystal structure of membrane fusion protein, MexA, of the multidrug transporter in Pseudomonas aeruginosa. J. Biol. Chem. 279 (2004) 25939-25942